Kornimate/medical-research-clean huggingface dataset:
tear dynamics after restasis treatment in dry eye patients

Conditions: Dry Eye

Summary: observe the changes of tear volume in dry eye patients after restasis treatment of 3 months and during 6-month follow-up after discontinuation of study treatment.

using an imaging device name optical coherence tomography to image the tear volume in dry eye patients before and after restasis treatment.

Eligibility criteria:
inclusion criteria: the participant will be eligible for entry in the study if s/he: 1. is at least 18 years old and has full legal capacity to volunteer; 2. has read and signed the irb informed consent document; 3. is willing and able to follow participant instructions; 4. has clear corneas; 5. has 20/100 uncorrected visual acuity or better; 6. has dry eye according to the study definition of des (study subjects); 7. has not use restasis within 3 months. exclusion criteria: the subjects will ineligible for entry into the study if s/he: 1. has any systemic disease affecting ocular health except for sjögren's syndrome; 2. is using any systemic or topical medications that will affect ocular health except for artificial tears; 3. has an active ocular disease other than des, or sjögren's syndrome 4. has any clinically significant lid or conjunctival abnormalities, neovascularization, corneal scars or corneal opacities; 5. has limbal or bulbar injection or corneal staining that was clinically significant, which are not due to des; 6. has worn rigid gas permeable lenses within 1 year and during the study; 7. has had surgery or an eye injury within 6 months; 8. was a soft contact lens wearer within 2 weeks and during the study.

Keywords: dry eye optical coherence tomography
utility of ultrasound imaging for diagnosis of focal liver lesions: a radiomics analysis

Conditions: Focal Liver Lesions; Ultrasonics; Intelligent Diagnosis; Ablation; Radiomics

Summary: ultrasound (us) as first-line imaging technology in detecting focal liver lesions,also plays a crucial role in evaluating image and guiding ablation which is the main treatment for liver lesions. however, the effect of us in diagnosing liver lesions is challenged by several factors including being highly dependent on doctor's experience, low signal-to-noise ratio, low resolution for lesion feature,large error from thermal field evaluation during the process of ablation and so on. therefore, it is of great significance to construct an intelligent us analysis system depending on the digital information technology. basing on these problems,the following research will be involved in our project: 1) us database of liver lesions with seamless connection to picture archiving and communication systems (pacs) will be developed, with the aim to provide standard data for intelligent us analysis. 2) deep learning model for accurate segmentation, detection and classification of liver lesions on us images will be studied. then automatic extraction, selection and analysis of liver lesion ultrasound features and the intelligent us diagnosis for liver lesions will be realized. 3) proposing a clustering model with deep image features, and depicting the similarity measurement of liver cancer, which can be furthered used to link the liver cancer feature to optimal ablation parameters. the intelligent decision-making system for quantifying thermal ablation will be established. 4) regression algorithm and generative adversarial nets will be developed to extract the image features of liver cancer which will predict risk factors after us-guided thermal ablation.based on the above researches, it is of great value to establish an intelligent focal liver lesion us diagnosis system involving intelligent diagnosis,personalized ablation strategy and accurate prognosis evaluation, improving the level of accurate diagnosis and treatment of liver lesions.


Eligibility criteria:
inclusion criteria: 1. clear ultrasound imaging of focal liver lesions including malignant liver tumors such as hepatocellular carcinoma, metastatic liver cancer and benigh liver tumors such as hemangioma and focal nodular hyperplasia and so on can be acquired. 2. clear ultrasound imaging of liver tissues backgroud without lesions can be acquired. 3. disease history and pathological diagnosis of the lesions can be acquired. exclusion criteria: 1. patients unsuitable for ultrasound san 2. patients counldn't provide disease history such as hepatitis, alcohol intake and so on 3. patients without pathological results
acute application of pegvisomant and octreotide in acromegaly

Conditions: Acromegaly

Summary: the purpose of the study is to investigate the efficacy of an acute additional application of the somatostatin analogue octreotide 100µg s.c. or the dopamine agonist cabergoline 0.5mg p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.


Eligibility criteria:
inclusion criteria: * patients with acromegaly currently on stable pegvisomant therapy * patients with diabetes mellitus may be included. glucose levels must be controlled regularly throughout the study * patients must not be co-treated with any other medication for acromegaly exclusion criteria: * radiotherapy within the last 2 years * any relevant acute disease * history of hypersensitivity against any of the used drugs * pregnancy or lactation * abnormal baseline findings

Keywords: acromegaly, growth hormone receptor antagonist, somatostatin analogue, combined medical treatment, acute effect, endogenous gh
effects of ue aerobic exercise on exercise capacity and pa in patients with pulmonary arterial hypertension.

Conditions: Pulmonary Arterial Hypertension (PAH)

Summary: group a will be training group and group b will be control group. deep breathing exercises will be done as baseline treatment in both groups. both groups will be assessed with modified borg scale, 6-pbrt and fatigue severity scale at the baseline. the control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. intervention will be for 3 times a week or 6 weeks. the treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist. training intensity will adjust according to 50 80 % of max hr or intensity of dyspnea to 4 points on modified borg scale (mbs) for at least 15 45 min, 3 times/week over 6 weeks.

group a will be training group and group b will be control group. deep breathing exercises will be done as baseline treatment in both groups. both groups will be assessed with modified borg scale, 6-pbrt and fatigue severity scale at the baseline. the control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. intervention will be for 3 times a week or 6 weeks. the treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist. training intensity will adjust according to 50 80 % of max hr or intensity of dyspnea to 4 points on modified borg scale (mbs) for at least 15 45 min, 3 times/week over 6 weeks. this study will measure and record hr by using the heart rate monitor, oxygen saturation (spo2) by using pulse oximetry and blood pressure, breathing frequency (bf), dyspnea, fatigue, and arm fatigue by using mbs before, during, and after training.

Eligibility criteria:
inclusion criteria: * patient diagnosed with pulmonary arterial hypertension. * both the sex was considered. * age range from 35 to 60 years. * patients who were stable. * patient under optimal medical therapy for at least three months before participating in this study * willing to participate in study (13). exclusion criteria: * patient with cognitive disorders. * patient with orthopedic or neurological diseases. acute infection or pneumonia * patient with class iv heart failure. * patient with acute infection or pneumonia.

Keywords: upper extremity aerobic exercise training; ; exercise capacity; rehabilitation
concurrent chemo-radiotherapy with capecitabine for unresectable locally advanced pancreatic carcinoma

Conditions: Pancreatic Cancer

Summary: the only curative option for pancreatic cancer patients is surgery, but the patients within 20% of them are possible for a radical surgery. accordingly, concurrent chemo-radiation therapy is generally used for palliation of unresectable pancreatic cancer patients. so far, the use of 5-fluorouracil (5-fu) was the traditional method of chemotherapy. however, these days, oral anti-cancer medicine, capecitabine(xeloda®), was developed and considered as an alternative medicine of 5-fluorouracil (5-fu). furthermore, according to the recent results of clinical trials, the clinical use of capecitabine(xeloda®) with radiation therapy was proved to be very effective and safe. the purpose of this trial is to improve the therapeutic effects by using proton therapy and chemotherapy concurrently.


Eligibility criteria:
inclusion criteria: * there is no evidence of metastatic disease in the major viscera and no peritoneal seeding * patients with biliary or gastroduodenal obstruction must have drainage prior to starting chemoradiation * all malignant disease must be encompassable within a single irradiation field (15x15cm maximum) * all patients must have radiographically assessable disease * no previous irradiation to the planned field * age of ≥18 years * performance status of 0 to 2 on the eastern cooperative oncology group (ecog) score * required entry laboratory parameters wbc count ≥ 2,000/mm3;(anc\>1,000), hemoglobin level ≥ 7.5 g/dl; platelet count ≥ 100,000/mm3; total bilirubin ≤ 3.0 mg/dl (patients with elevated bilirubin due to obstruction should be stented and their bilirubin should be decreas ≤ 3.0 mg/dl prior to study entry); creatinine ≤ 3.0 mg/dl * oral intake (including j-tube feeding) of ≥ 1,500 calories/day should be maintained. exclusion criteria: * there is evidence of metastasis in the major viscera or peritoneal seeding. * age of \<18 years * previous history of rt adjacent to planned field * poor performance status of 3 to 4 on the eastern cooperative oncology group (ecog) score * pregnant or breast feeding status * previous history of uncontrolled other malignancies within 2 years
evaluation of the effectiveness of the complex of carnitine orotate and biphenyl dimethyl dicarboxylate in the adjuvant therapy of chronic hepatitis d in real clinical practice: a prospective cohort study

Conditions: Chronic Viral Hepatitis B With Delta-Agent

Summary: the goal of this observational study is to evaluate the effectiveness of the carnitine-orotate complex and biphenyl dimethyl dicarboxylate in the adjuvant therapy of chronic hepatitis d in real clinical practice: a prospective cohort study


Eligibility criteria:
inclusion criteria: * patients of both sexes aged 18 to 75 years who are citizens of the republic of kazakhstan; * an established diagnosis of cgd (chronic viral hepatitis b with the delta agent); * patients who have contraindications to taking peg-inf-alpha2a and/or have failed treatment with peg-inf-alpha2a; * compensated liver disease ≤ cpt a (6 points); * patients without severe concomitant diseases; * patients who do not receive other adjuvant therapy (metabolic therapy drugs, essential phospholipids, ursodeoxycholic acid, glycyrrhizic acid, ademetionine and others); * patients who voluntarily signed the informed consent form. exclusion criteria: * patients taking coc for more than 4 weeks before inclusion in the study; * patients with contraindications to the coc; * decompensated liver disease severity class \> cpt a6; * patients taking peg-ifn-alpha 2a; * alcohol abuse according to the audit-c questionnaire; * pregnancy and lactation; * patients with coinfection with hiv, hcv; * gfr ≤ 15 ml/min/1.73 m2; * exclude patients with significant biochemical activity (alt, ast more than 10 uln) and total bilirubin more than 2 norms; * patients with other causes of liver damage; * drug addict people; * malignant formations of the liver and other organs (in history and currently) or a clinically significant increase in alpha-fetoprotein more than 5 times or more; * patient takes part in an interventional clinical trial.
a pilot study evaluating safety of sitagliptin combined with peg-ifn alfa-2a + ribavirin in chronic hepatitis c patients

Conditions: Hepatitis C

Summary: hepatitis c infection is a major public health problem with nearly 175 million infected individuals worldwide. although cure is possible, only 20-40% of patients spontaneously resolve infection and 40-80% of chronically infected patients (numbers vary depending on viral genotype) that receive pegylated-interferon-alfa2a/ribavirin therapy clear the virus and are sustained virologic responders (svr). still for many, the virus manages to circumvent natural immunity and current therapeutic strategies, resulting in significant morbidity and mortality. to better define the distinct clinical outcomes of hcv infection many investigators have performed candidate molecules screens or transcriptional profiling in order to identify correlates of viral clearance. one molecule that has gained significant attention is cxcl10 (also known as interferon-gamma induced protein-10 or ip-10) as an important negative prognostic biomarker. given that cxcl10 is produced by hepatocytes and mediates chemo-attraction of activated lymphocytes expressing the cxcl10-receptor, cxcr3, it is counter-intuitive as to why this chemokine correlates with therapeutic non-responsiveness. the investigators hypothesized and have now demonstrated that cxcl10 is being cleaved in situ, resulting in the generation of an antagonist form of the chemokine. based on the use of specific inhibitors, the investigators now propose to test whether protection of the agonist form of cxcl10 will increase responsiveness to peg-ifn-alfa2 / ribavirin therapy. this can be achieved using dppiv inhibitors, targeting the enzyme responsible for n-terminal truncation of cxcl10. if safety is confirmed, the efficacy of dppiv-inhibition in hcv patients will be tested in future trials that examine potential clearance benefits.


Eligibility criteria:
inclusion criteria: * age between 18 and 70 years * for women, effective contraception during the trial and a negative pregnancy test (urine) before enrollment * patients naïve to prior hepatitis c treatment * confirmed hcv infection, based on the presence of hcv antibodies and plasma viremia allowing a measure of the circulating viral load * infection with hcv genotype 1 or 4 * intent of treatment alfa2 pegylated ifn-/ ribavirin exclusion criteria: * hbv infection * hiv infection * severe anemia (hb \<7-8 g / dl) * renal failure (creatinine clearance \<60 ml / min) * taking digoxin within 6 months of starting treatment. * taking immunosuppressants within 6 months of starting treatment * history of serious hypersensitivity reaction (such as anaphylactic shock or angioedema) to sitagliptin * patients with type i and ii diabetes * pregnancy or absence of effective contraception * a person deprived of liberty by judicial or administrative decision * living conditions-suggesting an inability to track all scheduled visits by the protocol

Keywords: chronic hepatitis c interferon protein 10 chemokine gradients sitagliptin
rehabilitation of facial emotion recognition in alzheimer's disease

Conditions: Alzheimer Dementia; Family Caregivers

Summary: this study aims to evaluate impacts of an emotion recognition rehabilitation program, named training of affect recognition, on social cognition abilities in alzheimer's disease (ad). in addition, we hypothesis that the effect of this rehabilitation will also evolve gaze strategies, behavioral disorders, and the caregiver's burden.

it is commonly admitted that social cognition impairment, like deficit in facial emotion recognition or misinterpretation of others' intentions (theory of mind), are associated with social behavior disorders. this kind of disorders are observed in fronto-temporal dementia, alzheimer's dementia (ad) and parkinson's disease, with severe deficits in ftd and lighter deficits in ad and pd. one explanation is that patients apply inappropriate visual exploration strategies to decode emotions and intentions of others. our study aims to evaluate impacts of an emotion recognition rehabilitation program, named training of affect recognition, on social cognition abilities (facial emotion recognition (fer) and theory of mind (tom)) in alzheimer's disease (ad). in addition, we hypothesis that the effect of this rehabilitation will also evolve gaze strategies, behavioral disorders, and the caregiver's burden.

Eligibility criteria:
inclusion criteria: * ad diagnosed according to l'iwg-2 (dubois \& al. 2014) criteria, * mini-mental state (mms-e) ≥15 * subject accompanied by a family caregiver and whose participation in a cognitive stimulation workshop was recommended in memory centre of the rainier centre (princesses grace hospital - monaco) * written informed consent signed by patient and family caregiver. exclusion criteria: * general anaesthesia within 3 months. * ophthalmological or neurological problems preventing a video-oculography examination. * oculomotor disorders such as "fixation disorders" or "ocular tracking disorders". * cognitive disorders of the type: visual agnosia, visuo-spatial disorder, visuo-perceptual disorder or aphasia. * history of bipolar disorder or schizophrenia * history of alcohol abuse.

Keywords: video-oculography eye-tracking gaze strategies oculomotor behaviors training of affect recognition emotion recognition facial emotion recognition theory of mind (tom) behavioral disorders caregiver's burden alzheimer's dementia
safety and efficacy study of bimatoprost/timolol fixed combination in patients with glaucoma or ocular hypertension

Conditions: Ocular Hypertension

Summary: the purpose of this study is to assess the safety and efficacy of bimatoprost/timolol fixed combination in patients with glaucoma or ocular hypertension


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes * patient requires iop-lowering drug in both eyes exclusion criteria: * uncontrolled medical condition * contraindication to beta-adrenoceptor antagonist therapy
study evaluating enbrel (etanercept) in adult patients with plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the purpose of this study is to investigate the incidences of adverse events for patients with plaque psoriasis treated with enbrel under usual care settings.


Eligibility criteria:
inclusion criteria: * proven diagnosis of plaque psoriasis exclusion criteria: * contraindications according to smpc of enbrel
tumor growth factors in hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: malignant cells frequently produce many tumor growth factors to autocidal or endocrinal proliferate growth, metastasis,or angiogenesis about tumor cells. by studying tumor growth factors in hepatocellular carcinoma, one may know the tumor behavior, its relationship with clinical manifestation or invasion, and could be used as diagnostic or prognostic tools.this study aims to study the relationship between tumor growth factors in hcc ant its clinical relevance.

the clinical relevance of patients will be evaluated by the concentrations of tumor growth factors.

Eligibility criteria:
inclusion criteria: * histology proven hcc exclusion criteria: * no definitely diagnosed tumor

Keywords: tumor growth factor
study of ibuprofen to preserve lung function in patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: objectives: i. determine the effect of different doses of ibuprofen on neutrophil (polymorphonuclear leukocyte; pmn) delivery to a mucosal surface (the oral mucosa) in patients with cystic fibrosis and healthy controls. ii. determine the duration of effect (and possible rebound effect) of ibuprofen on pmn delivery to a mucosal surface in these patients.

protocol outline: this is an open label study. patients are randomized into 5 arms, each consisting of 10 healthy volunteers and 5 patients with cystic fibrosis, based on the amount of ibuprofen received during the treatment period. the study period lasts for at least 15 days and consists of 3 periods: baseline (days 1-3), treatment (days 3-12), and recovery (days 13-15 or longer). during the treatment period patients receive ibuprofen orally every 12 hours (except for a control arm that receives no ibuprofen).

Eligibility criteria:
protocol entry criteria: --disease characteristics-- confirmed diagnosis of cystic fibrosis (cf) based on: sweat chloride greater than 60 meq/l and typical pulmonary and/or gastrointestinal manifestation of cf or healthy volunteers --prior/concurrent therapy-- at least 30 days since medications with anti-neutrophil or anti-inflammatory effect (e.g., aspirin, nonsteroidal anti-inflammatory drugs \[nsaids\], corticosteroids, macrolide antibiotics) --patient characteristics-- age: patients with cystic fibrosis (cf): 5 and over; healthy volunteers: 18 and over hematopoietic: no significant history of hematologic disease hepatic: no significant history of hepatic disease renal: no significant history of renal disease cardiovascular: no significant history of cardiovascular disease pulmonary: see disease characteristics neurologic: no significant history of neurologic disease other: not pregnant; no significant history of peptic ulcer disease; patients with cf free of any acute illness within 14 days; no prior hypersensitivity to any nsaid

Keywords: cardiovascular and respiratory diseases cystic fibrosis genetic diseases and dysmorphic syndromes rare disease
safety study of single administration post-exposure prophylaxis treatment for marburg virus

Conditions: Marburg Hemorrhagic Fever

Summary: the purpose of this study is to characterize the safety and pharmacology of single administrations of avi-6003, a post-exposure prophylaxis candidate treatment for marburg virus.

marburg hemorrhagic fever is a rare human disease caused by the marburg virus, a filamentous, single-stranded, negative-sense rna virus. in general, the mortality rate associated with marburg virus outbreaks has ranged from 23% to 88%, with the highest death rates seen in more recent epidemics. no vaccine or effective therapy is available for marburg hemorrhagic fever. avi-6003 is an experimental combination of 2 phosphorodiamidate morpholino antisense oligomers with positive charges on selected subunits (pmoplus™). these oligomers specifically target viral messenger rna encoding 2 marburg virus proteins thought to be important in viral replication and host immune suppression. the present study is designed to characterize the safety, tolerability and pharmacokinetics of escalating single-administration doses of avi-6003 in healthy human subjects.

Eligibility criteria:
inclusion criteria: * male or female and between the ages of 18 and 50 years in good general health * volunteers must be willing to use barrier methods of contraception or be of non-childbearing potential * volunteers must be willing to undergo a urine screen for drugs of abuse exclusion criteria: * pregnancy or breastfeeding. * any clinically relevant abnormalities in physical examinations, vital signs, ecg, clinical chemistry, hematology or urinalysis * positive test for human immunodeficiency virus, hepatitis b or hepatitis c or known history of hiv infection